Skip to content

The Mechanism Study of Hua Tuo's Five-Animal Frolics on Immune Inflammation Homeostasis Regulation and Heterotopic Ossification in Ankylosing Spondylitis

The Mechanism Study of Hua Tuo's Five-Animal Frolics on Immune Inflammation Homeostasis Regulation and Heterotopic Ossification in Ankylosing Spondylitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000756
Enrollment
Unknown
Registered
2024-11-30
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis

Interventions

Study group control group and healthy control group:On the basis of the control group combined with Hua Tuo's Five-Animal Frolics
Healthy control group:Hua Tuo's Five-Animal Frolics
Control group:Celecoxib capsules plus sulfasalazine treatment basis

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the following diagnostic criteria: AS patients according to the New York criteria for the diagnosis of ankylosing spondylitis revised by the American Society of Rheumatology (ACA) in 1984 and the inflammatory low back pain (IBP) criteria established by the 2009 International Working Group for the Evaluation of spinal arthrosis (ASAS) and the new central axis SpA standard; (2) Age: 18-75 years old; (3) Patients with drugs (except SASP) such as triptrix prednisone (10mg) or other equivalent hormones should be stable for at least one month; (4) Voluntary participation in and actively cooperate with the treatment.

Exclusion criteria

Exclusion criteria: (1) Do not meet the following diagnostic criteria: AS patients according to the New York diagnostic criteria of ankylosing spondylitis revised by the American Society of Rheumatology (ACA) in 1984 and the inflammatory low back pain (IBP) criteria established by the 2009 International Working Group for Evaluation of spinal arthrosis (ASAS) and the new central axis SpA standard; (2) Combined with serious diseases such as heart liver and kidney and severe extra-articular manifestations; (3) those allergic to the study drug; (4) Advanced patients with severe joint deformity and rigidity and complete loss of joint function; (5) Patients with communication disorders and patients with other diseases.

Design outcomes

Primary

MeasureTime frame
Efficacy evaluation;Disease activity;

Secondary

MeasureTime frame
The expression of IL-17 / NF- ? B and Smad pathway;Bath Ankylosing Spondylitis Functional Index;Bath Ankylosing Spondylitis Disease Activity Index;Pillow-Wall Distance;Magnetic Resonance Imaging and Full Spine X-ray;Visual Analogue Scale for Patient's Overall Assessment;Bath Ankylosing Spondylitis Metrology Index;Schober's Test ;

Countries

China

Contacts

Public ContactHuang Chuanbin

The First Affiliated Hospital of Anhui University of Chinese Medicine

chuanbinh@163.com13865922531

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026